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Chronic pain is associated with cognitive deficits. Palmitoylethanolamide (PEA) has been shown to ameliorate 
pain and pain-related cognitive impairments by restoring glutamatergic synapses functioning in the spared 
nerve injury (SNI) of the sciatic nerve in mice. SNI reduced mechanical and thermal threshold, spatial memory 
and LTP at the lateral entorhinal cortex (LEC)-dentate gyrus (DG) pathway. It decreased also postsynaptic 
density, volume and dendrite arborization of DG and increased the expression of metabotropic glutamate 
receptor 1 and 7 (mGluR1 and mGluR7), of the GluR1, GluR1s845 and GluR1s831 subunits of AMPA receptor 
and the levels of glutamate in the DG. The level of the endocannabinoid 2-arachidonoylglycerol (2-AG) was 
instead increased in the LEC. Chronic treatment with PEA, starting from when neuropathic pain was fully 
developed, was able to reverse mechanical allodynia and thermal hyperalgesia, memory deficit and LTP in SNI 
wild type, but not in PPARα null, mice. PEA also restored the level of glutamate and the expression of 
phosphorylated GluR1 subunits, postsynaptic density and neurogenesis. Altogether, these results suggest that 
neuropathic pain negatively affects cognitive behavior and related LTP, glutamatergic synapse and 
synaptogenesis in the DG. In these conditions PEA treatment alleviates pain and cognitive impairment by 
restoring LTP and synaptic maladaptative changes in the LEC-DG pathway. These outcomes open new 
perspectives for the use of the Nacylethanolamines, such as PEA, for the treatment of neuropathic pain and 
its central behavioural sequelae. 
 
